Article Sidebar

PDF
Date Published: 13/01/2022
Abstract Views: 471
Views PDF: 289
DOI: https://doi.org/10.51298/vmj.v509i2.1817
Issue
Vol. 509 No. 2 (2021)
Section
Các bài báo
How to Cite
Thu Giang, T. ., Triệu Hùng, Đặng ., & Hoài Thu, P. . (2022). BISPHOSPHONATE-RELATED OSTEONECROSIS OF THE JAW: A TWO-CASE REPORT. Vietnam Medical Journal, 509(2). https://doi.org/10.51298/vmj.v509i2.1817

BISPHOSPHONATE-RELATED OSTEONECROSIS OF THE JAW: A TWO-CASE REPORT

Trần Thu Giang1,2,, Đặng Triệu Hùng1,2, Phạm Hoài Thu1,2
1 Hanoi Medical University
2 Hanoi Medical University Hospital

Main Article Content

Abstract

Osteonecrosis of the jaw is a complication of osteoporosis treatment by bisphosphonate, which can cause serious issues for patients. This is a rare complication with unspecific symptoms and signs, and so makes it difficult to diagnose at early stage. Thus, leads to severe jaw destruction and needs to operate. In Hanoi Medical University hospital, we had two patients who diagnosed with oral bisphosphonate-related osteonecrosis of the jaw. Both patients were under operation to remove death bone and brought good results.

Article Details

Keywords

osteonecrosis of the jaw, bisphosphonate, osteoporosis

References

1. Nguyễn Thị Thanh Hương, Phạm Thị Minh Đức. Phát triển một mô hình tiên lượng loãng xương cho phụ nữ Việt Nam. Thời sự Y học. 2007;15:7-13.
2. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. Journal of Oral and Maxillofacial Surgery. 2003;61(9):1115-1117. doi:10.1016/S0278-2391(03)00720-1
3. Khan AA, Morrison A, Hanley DA, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015;30(1):3-23. doi:10.1002/jbmr.2405
4. Cosman F, de Beur SJ, LeBoff MS, et al. Clinician’s Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int. 2014;25(10):2359-2381. doi:10.1007/s00198-014-2794-2
5. Abe T, Sato T, Kokabu S, et al. Zoledronic acid increases the circulating soluble RANKL level in mice, with a further increase in lymphocyte-derived soluble RANKL in zoledronic acid- and glucocorticoid-treated mice stimulated with bacterial lipopolysaccharide. Cytokine. 2016;83:1-7. doi:10.1016/j.cyto.2016.03.012
6. Yamazaki T, Yamori M, Yamamoto K, et al. Risk of osteomyelitis of the jaw induced by oral bisphosphonates in patients taking medications for osteoporosis: A hospital-based cohort study in Japan. Bone. 2012;51(5):882-887. doi:10.1016/j.bone.2012.08.115
7. Ruggiero SL, Dodson TB, Fantasia J, et al. American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update. Journal of Oral and Maxillofacial Surgery. 2014;72(10):1938-1956. doi:10.1016/j.joms.2014.04.031
8. Hellstein JW, Adler RA. Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis. Recommendations from the American Dental Association Council on Scientific Affairs.2011.
9. Adler RA, El-Hajj Fuleihan G, Bauer DC, et al. Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016;31(1):16-35. doi:10.1002/jbmr.2708